Core Systemic Regimens For Metastatic Gastric Adenocarcinoma

Managing advanced, unresectable, or metastatic stomach cancer relies on targeted biological agents and immune checkpoint inhibitors integrated with multi-agent chemotherapy backbones. Modern oncological standards mandate immediate, comprehensive molecular biomarker testing prior to selecting first-line therapy. Identifying specific surface proteins and genomic alterations allows multidisciplinary care teams to deliver personalized systemic regimens, extending overall survival while controlling disease-related symptoms.

[Advanced / Metastatic Gastric Adenocarcinoma]
                       │
                       ▼
         [Mandatory Biomarker Testing]
   (HER2, PD-L1 CPS/TAP, CLDN18.2, MSI/dMMR)
                       │
   ┌───────────────────┼───────────────────┬───────────────────┐
   ▼                   ▼                   ▼                   ▼
[HER2-Positive]   [CLDN18.2-Pos.]    [MSI-High / dMMR]   [PD-L1 Positive]
(IHC 3+ / FISH+)   (IHC ≥75% 2+/3+)   (Mismatch Repair)   (CPS/TAP ≥1%)
   │                   │                   │                   │
   ▼                   ▼                   ▼                   ▼
Zanidatamab OR     Zolbetuximab        Immune Checkpoint   Pembrolizumab OR
Pembrolizumab +    + mFOLFOX6          Inhibitors (Anti-   Nivolumab +
Trastuzumab +      Chemotherapy        PD-1 Monotherapy)   mFOLFOX6 / CAPOX
Chemotherapy                                

Essential Molecular Profiling Framework

Before initiating systemic treatment, tissue biopsies undergo mandatory testing to establish the molecular subtype of the tumor.

• HER2 Status (ERBB2 Overexpression): Assessed via immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). HER2-positivity determines eligibility for anti-HER2 targeted monoclonal and bispecific antibodies.
• PD-L1 Expression Levels: Measured using the Combined Positive Score (CPS) or Tumor Area Positivity (TAP). Higher scores indicate greater probability of response to anti-PD-1 immune checkpoint inhibitors.
• Claudin 18.2 (CLDN18.2) Biomarker: Assessed by IHC to identify tumors exhibiting high tight-junction protein expression.
• Microsatellite Instability (MSI-H / dMMR): Evaluated via polymerase chain reaction (PCR) or next-generation sequencing (NGS) to identify mismatch repair deficiency.

First-Line Biomarker-Driven Systemic Regimens

Systemic treatment choice depends on the specific biomarker profile identified during initial diagnostic workup.

Target BiomarkerFirst-Line Systemic CombinationPrimary Clinical ObjectiveHER2-PositiveZanidatamab OR Pembrolizumab + Trastuzumab + Platinum/FluoropyrimidineDual HER2 blockade or immune enhancement combined with cytotoxic chemotherapy to maximize response rates.CLDN18.2-PositiveZolbetuximab + mFOLFOX6 ChemotherapyTargeted monoclonal antibody binding to claudin proteins, triggering antibody-dependent cellular cytotoxicity.PD-L1 Positive (CPS ≥1)Pembrolizumab or Nivolumab + Platinum/FluoropyrimidineReactivates T-cell immune response against tumor cells while maintaining cytotoxic tumor debulking.MSI-High / dMMRSingle-Agent or Combination Anti-PD-1 ImmunotherapyCapitalizes on high tumor mutational burden to induce durable, long-term immune-mediated remissions.

Second-Line Strategies and Antibody-Drug Conjugates (ADCs)

When disease progression occurs following first-line therapy, second-line strategies shift toward alternative targeted agents and cytotoxic formulations.

HER2-Directed Antibody-Drug Conjugates

For HER2-positive metastatic disease that progresses past initial trastuzumab-based therapy, antibody-drug conjugates like trastuzumab deruxtecan deliver potent chemotherapy payloads directly into HER2-expressing tumor cells, demonstrating superior survival over traditional chemotherapy options.

Anti-Angiogenic and Cytotoxic Combinations

For HER2-negative tumors progressing after first-line regimens, anti-angiogenic therapy combining ramucirumab (a VEGFR-2 antagonist) with paclitaxel remains a standard second-line pathway to restrict tumor vascularization and slow progression.

Supportive Care and Multidisciplinary Management

Advanced stomach cancer treatment integrates aggressive palliative and supportive interventions alongside systemic therapies. Palliative surgical bypass, endoscopic stent placement, or localized radiation therapy resolve physical gastric outlet obstructions and control tumor bleeding. Concurrently, specialized clinical nutrition teams address cancer cachexia, supporting metabolic stability and preserving performance status throughout ongoing treatment cycles.

Conclusion

Managing advanced stomach cancer requires an individualized, biomarker-driven treatment approach. By combining comprehensive molecular profiling for HER2, PD-L1, CLDN18.2, and MSI status with targeted therapeutics, immunotherapies, and combination chemotherapy backbones, clinical teams can optimize systemic response rates. Adhering to updated evidence-based guidelines ensures that patients receive precise, targeted interventions that prolong survival while maintaining overall quality of life.